Deep Genomics vs Healx

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Deep Genomics employs 100-500 people, while Healx has 1-50 employees.

Deep Genomics has raised more in total funding at $180M, compared to Healx's $47M — a gap of $133M.

Deep Genomics holds the higher Awaira Score at 68/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 13-point gap that reflects meaningful differences in scale or traction.

Deep Genomics was founded by Brendan Frey in 2015. Healx was founded by Tim Guilliams in 2014. Visit each company's profile on Awaira for a full founder biography.

Deep Genomics: Deep Genomics applies deep learning to genetic medicine discovery, using AI models trained on genomic sequence data to predict the functional consequences of genetic variants, identify RNA splicing defects that underlie genetic diseases, and generate novel therapeutic candidates including antisense oligonucleotides and small molecules that correct disease-causing genetic variants. The Toronto company was founded by Brendan Frey, a University of Toronto machine learning professor who collaborated with Geoffrey Hinton on deep learning research.\n\nThe company raised approximately $180 million in venture funding from investors including True Ventures, AlleyCorp, and GV (Google Ventures). Deep Genomics has built an AI drug discovery platform called the AI Workbench that integrates genomic data, disease biology, and AI prediction across the therapeutic discovery pipeline, and has entered a strategic alliance with Agenus to develop cancer treatments using its AI-designed oligonucleotide candidates.\n\nDeep Genomics competes in the AI genetic medicine space against Recursion Pharmaceuticals, Insitro, Exscientia, and gene therapy companies building computational biology capabilities. Its specific focus on RNA biology and oligonucleotide therapeutics, which represent a growing class of approved genetic medicines, differentiates it from platforms focused on small molecule drug discovery or cell therapy. The Toronto University of Toronto AI ecosystem, including connections to the Vector Institute and the Hinton research lineage, provides research credibility and talent access that distinguishes Canadian AI drug discovery from international competitors. Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised.

Healx was founded first in 2014, giving it 1 year of additional market experience. Deep Genomics was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Deep Genomics has approximately 100-500 employees, while Healx has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Deep Genomics and Healx are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.